Logo
x

Search

Subscribe Now

All Posts by Date

BridgeBio Collaborates with Helsinn to Co- Develop and Commercialize Infigratinib in Oncology

BridgeBio Collaborates with Helsinn to Co- Develop and Commercialize Infigratinib in Oncology

  • April 1, 2021
BioXcel Report Results of BXCL501 in P-Ib/II RELEASE Study for the Treatment of Opioid Withdrawal Symptoms

BioXcel Report Results of BXCL501 in P-Ib/II RELEASE Study for the Treatment of Opioid Withdrawal Symptoms

  • April 1, 2021
Amryt Reports NDA Submission for Oleogel-S10 (filsuvez) to Treat Cutaneous Manifestations of Junctional and Dystrophic Epidermolysis Bullosa

Amryt Reports NDA Submission for Oleogel-S10 (filsuvez) to Treat Cutaneous Manifestations of Junctional and Dystrophic Epidermolys...

  • April 1, 2021
ADQ to Acquire Amoun Pharmaceutical from Bausch Health for ~$740M

ADQ to Acquire Amoun Pharmaceutical from Bausch Health for ~$740M

  • April 1, 2021
Sanofi's Sarclisa (isatuximab-irfc) + Carfilzomib and Dexamethasone Receives the US FDA's Approval for the Treatment of R/R Multiple Myeloma

Sanofi's Sarclisa (isatuximab-irfc) + Carfilzomib and Dexamethasone Receives the US FDA's Approval for the Treatment of R/R Multip...

  • April 1, 2021
Alnylam Report Results of Lumasiran in P-III ILLUMINATE-A Study for Primary Hyperoxaluria Type 1- Published in NEJM

Alnylam Report Results of Lumasiran in P-III ILLUMINATE-A Study for Primary Hyperoxaluria Type 1- Published in NEJM

  • April 1, 2021
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.